Photodynamic therapy for cholangiocarcinoma

Area of Science:

• Oncology
• Gastroenterology
• Medical Therapy

Background:

• Nonresectable cholangiocarcinoma, particularly Bismuth types III and IV, has a poor prognosis.
• Relief of jaundice is often challenging even after successful endoprosthesis insertion.
• Limited treatment options exist for patients who fail to respond to initial interventions.

Purpose of the Study:

• To evaluate the efficacy of additional photodynamic therapy (PDT) in patients with nonresectable cholangiocarcinoma who did not respond to endoprosthesis insertion.
• To assess improvements in jaundice, quality of life, and survival rates.
• To gather preliminary data for a larger randomized multicenter trial.

Main Methods:

• Twenty-one patients with nonresectable cholangiocarcinoma received photodynamic therapy (using Photofrin) in addition to endoscopic drainage.
• Hematoporphyrin derivative Photofrin was administered intravenously, followed by intraluminal photoactivation.
• Patient outcomes were assessed based on bilirubin levels, Karnofsky index, and survival time.

Main Results:

• Mean bilirubin levels decreased significantly from 201.26 micromol/l to 68.87 micromol/l (P = 0.0051) after PDT.
• The Karnofsky index, a measure of quality of life, improved from 49.04% to 72.85% (P = 0.003).
• The 6-month survival rate was 95%, with a median survival of 439 days.

Conclusions:

• Photodynamic therapy is a promising adjunctive treatment for nonresectable cholangiocarcinoma, improving jaundice, quality of life, and survival in non-responders to stenting.
• Preliminary results support the initiation of a randomized multicenter trial to further validate these findings.
• Observed improvements align with findings from other research groups, indicating consistent efficacy.